Takeda Pharmaceutical/$TAK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Tokyo, Japan
Employees
47,455
ISIN
US8740602052
Website
TAK Metrics
BasicAdvanced
$47B
32.63
$0.45
0.26
$0.54
3.74%
Price and volume
Market cap
$47B
Beta
0.26
52-week high
$15.53
52-week low
$12.80
Average daily volume
2.4M
Dividend rate
$0.54
Financial strength
Current ratio
1.006
Quick ratio
0.443
Long term debt to equity
64.522
Total debt to equity
73.365
Dividend payout ratio (TTM)
280.28%
Interest coverage (TTM)
4.31%
Profitability
EBITDA (TTM)
8,134.641
Gross margin (TTM)
65.70%
Net profit margin (TTM)
2.36%
Operating margin (TTM)
9.80%
Effective tax rate (TTM)
38.23%
Revenue per employee (TTM)
$648,810
Management effectiveness
Return on assets (TTM)
1.91%
Return on equity (TTM)
1.52%
Valuation
Price to earnings (TTM)
32.626
Price to revenue (TTM)
0.756
Price to book
1
Price to tangible book (TTM)
-3.46
Price to free cash flow (TTM)
4.882
Free cash flow yield (TTM)
20.48%
Free cash flow per share (TTM)
301.91%
Dividend yield (TTM)
3.68%
Forward dividend yield
3.74%
Growth
Revenue change (TTM)
7.45%
Earnings per share change (TTM)
-26.25%
3-year revenue growth (CAGR)
8.68%
10-year revenue growth (CAGR)
9.93%
3-year earnings per share growth (CAGR)
-22.76%
10-year earnings per share growth (CAGR)
-9.65%
3-year dividend per share growth (CAGR)
2.88%
10-year dividend per share growth (CAGR)
0.86%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Bulls say / Bears say
Takeda reported a 13.4% year-over-year revenue increase, reaching JPY 2,384 billion, driven by strong performance in Plasma-Derived Therapies, Oncology, and Vaccines. (TipRanks)
The company has entered into multiple licensing agreements with Indian pharmaceutical firms to market Vonoprazan, expanding its gastrointestinal product portfolio in the Indian market. (The Economic Times)
Takeda's strategic partnership with Biological E Ltd aims to manufacture up to 100 million doses of its dengue vaccine annually, enhancing its presence in the global vaccine market. (Business Standard)
Takeda announced layoffs of 641 employees in Massachusetts as part of a restructuring plan, indicating potential operational challenges. (Wikipedia)
The company is withdrawing its lung cancer drug, Exkivity, from the U.S. market after a failed late-stage study, which may impact its oncology portfolio. (Wikipedia)
Takeda's Q3 2025 profits slid 38%, trailing analyst estimates, suggesting financial performance concerns. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Business Wire·4 days ago
Takeda Announces New Assignments of Directors
Business Wire·3 weeks ago
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $47B as of July 18, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 32.63 as of July 18, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of July 18, 2025, the dividend rate is $0.54312 and the yield is 3.74%. Takeda Pharmaceutical has a payout ratio of 280.28% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.